About FDA

Office of Translational Sciences

Our Mission

The Office of Translational Sciences (OTS) promotes and protects public health by:

  • Promoting scientific collaboration and innovation in drug regulatory review across CDER
  • Assuring the validity of clinical trial design and analysis in regulatory decision making
  • Developing and applying quantitative and statistical approaches to decision making in the regulatory review process
  • Ensuring alignment of CDER research with CDER goals
  • Serving the CDER scientific community in establishing technology transfer agreements that are vital to collaboration with the wider scientific community
  • Maintaining knowledge management databases that can be the basis of improvements in the regulatory review process
  • Overseeing bioequivalence inspections to ensure the availability of safe and effective generic equivalents of investigational drugs
Whats new in regulatory science


Enter your email address to get updates about CDER Regulatory Science Initiatives.


Director: ShaAvhrée Buckman-Garner, M.D., Ph.D.


Office of Biostatistics

  • The Office of Biostatistics (OB) provides leadership, direction, policy development, and coordination to CDER on statistical, mathematical, and computational aspects of review, evaluation, and research

Office of Computational Science

  • The Office of Computational Science (OCS) provides CDER reviewers innovative solutions that improve the scientific drug review process by integrating data, tools, services, and training.

Office of Clinical Pharmacology

  • The Office of Clinical Pharmacology (OCP) assures the safety and effectiveness of new drugs through the evaluation of clinical pharmacology and biopharmaceutics data in support of CDER’s Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA) review programs.

Office of Study and Integrity and Surveillance

  • The Office of Study and Integrity and Surveillance (OSIS) ensures data supporting regulatory decisions are reliable by conducting and directing inspections of bioavailability/bioequivalence (BA/BE) and nonclinical (GLP) studies submitted to FDA.

Contact Us

White Oak Building 21 – 4th Floor
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 301-796-2600
Fax: 301-796-9907

Back to Top

Additional Resources

  • Office of Biostatistics
    The Biomarker Qualification Program was established to support the Center for Drug Evaluation and Research’s (CDER's) work with external stakeholders to develop biomarkers that aid in the drug development process.
  • Critical Path Initiative
    The Critical Path Initiative (CPI) is FDA's strategy to drive innovation in the scientific processes through which medical products are developed, evaluated, and manufactured.
  • Critical Path Innovation Meetings (CPIM)
    The CPIM is a means by which the Center for Drug Evaluation and Research (CDER) and investigators from industry, academia, patient advocacy groups, and government can communicate to improve efficiency and success in drug development.
  • ORISE Fellowship
    The ORISE Research Participation Programs at FDA are educational and training programs designed to provide students, recent graduates, and university faculty opportunities to participate in project-specific FDA research and developmental activity.
  • Science & Research (Drugs)

Back to Top



Page Last Updated: 03/01/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English